The consensus price target hints at a 102.7% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...
HUTCHMED (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could...
The mean of analysts' price targets for HUTCHMED (HCM) points to a 61.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...
SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today...
HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...